admin | April 6, 2021
Researchers at the American Association for Cancer Research recently published an article, “Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms,” highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients. Utilization of checkpoint blockades confirmed mut-CALR as an effective immunogen that can be used as an MPN-specific neoantigen. Current MPN treatments do not effectively target these malignant CALR cells, but these findings are potentially promising for the future of MPN immunotherapy.